Proceedings of the International symposium on Sustainable Drug Design and Nanoparticle development: Quantum and Computational Perspectives (SDDNDQCP 2025)

<Previous Article In Volume
Next Article In Volume>

Development and Validation of A Novel UPLC Method for Simultaneous Estimation of Simnotrelvir and Ritonavir in Bulk and Pharmaceutical Dosage Forms

Authors
Gope Edward Raju1, *, Srikanth Pottendla2, Suneetha Yaparthi2
1Research Scholar, University College of Pharmaceutical Sciences, Acharya Nagarjuna University, Nagarjuna Nagar, Guntur, Andhra Pradesh, India
2Samuel George Institute of Pharmaceutical Sciences, Markapur, Andhra Pradesh, India
*Corresponding author. Email: edward.phd.2022@gmail.com
Corresponding Author
Gope Edward Raju
Available Online 13 August 2025.
DOI
10.2991/978-94-6463-813-4_3How to use a DOI?
Keywords
Simnotrelvir; Ritonavir; Development; UPLC
Abstract

A simple, accurate, and precise method was developed to estimate Simnotrelvir and Ritonavir in pharmaceutical dosage form. Chromatography is used on a phenyl column (‘2.1 mm x 100 mm, 1.7 µm’) using a ‘mobile phase’ consisting of ‘0.1% formic acid’ and acetonitrile in ‘60:40 v/v’ ‘ratio’, with a ‘flow rate of 0.5 mL/min’.’ Retention’’ ‘time’ of Simnotrelvir and ‘Ritonavir’ ‘were’ 1.113 min & 1.875 ‘min’ and total run time for the method was 2.50 min. ‘Method’ exhibited ‘good’ ‘linearity’ ‘with’ ‘correlation coefficients (R2)’ of ‘0.999’ for both drugs over the concentration ranges of 93.75–562.50 µg/mL for Simnotrelvir and ‘25.00–150.00 µg/mL’ for ‘Ritonavir’. The optimized ‘method’ demonstrated good recovery results for both drugs, confirming its accuracy and precision. The ‘method’ was ‘validated’ for’ specificity, ‘linearity’, ‘accuracy’, ‘precision’, robustness, degradation. Results indicate that the method is suitable for general daily quality control’ analysis of Simnotrelvir. Ritonavir in ‘pharmaceutical formulations.

Copyright
© 2025 The Author(s)
Open Access
Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Download article (PDF)

<Previous Article In Volume
Next Article In Volume>
Volume Title
Proceedings of the International symposium on Sustainable Drug Design and Nanoparticle development: Quantum and Computational Perspectives (SDDNDQCP 2025)
Series
Advances in Health Sciences Research
Publication Date
13 August 2025
ISBN
978-94-6463-813-4
ISSN
2468-5739
DOI
10.2991/978-94-6463-813-4_3How to use a DOI?
Copyright
© 2025 The Author(s)
Open Access
Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Cite this article

risenwbib
TY  - CONF
AU  - Gope Edward Raju
AU  - Srikanth Pottendla
AU  - Suneetha Yaparthi
PY  - 2025
DA  - 2025/08/13
TI  - Development and Validation of A Novel UPLC Method for Simultaneous Estimation of Simnotrelvir and Ritonavir in Bulk and Pharmaceutical Dosage Forms
BT  - Proceedings of the International symposium on Sustainable Drug Design and Nanoparticle development: Quantum and Computational Perspectives (SDDNDQCP 2025)
PB  - Atlantis Press
SP  - 14
EP  - 25
SN  - 2468-5739
UR  - https://doi.org/10.2991/978-94-6463-813-4_3
DO  - 10.2991/978-94-6463-813-4_3
ID  - Raju2025
ER  -